Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.31)
# 269
Out of 4,814 analysts
125
Total ratings
38.74%
Success rate
30.38%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $69 → $65 | $23.96 | +171.34% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.34 | +488.24% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $6.09 | +228.41% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $0.42 | +622.02% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $12.72 | +175.16% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $11.21 | +238.98% | 7 | Feb 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $23.83 | +302.85% | 2 | Feb 7, 2025 | |
| NKTR Nektar Therapeutics | Initiates: Buy | $4 | $0.64 | +525.00% | 1 | Jan 8, 2025 | |
| CGTX Cognition Therapeutics | Upgrades: Buy | $1 → $1.5 | $0.37 | +309.95% | 3 | Dec 19, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $194 → $236 | $301.73 | -21.78% | 11 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $6.00 | +333.33% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $12.25 | +169.39% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $4.54 | +340.53% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $38.32 | -11.27% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $5 | $1.27 | +293.70% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $39.48 | +133.03% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.02 | -0.50% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $6.02 | -33.55% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.19 | +1,462.50% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $2.08 | +7,592.31% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.79 | +179.33% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $1.44 | +2,955.56% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.51 | +5,860.26% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $7.35 | -4.76% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.27 | +354,230.71% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $0.79 | +33,939.33% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $10.51 | +632.64% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.34 | +107,362.69% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.38 | +189.86% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $82.73 | -52.86% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.45 | +658.62% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.51 | +868.66% | 1 | Mar 13, 2020 |
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $23.96
Upside: +171.34%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.34
Upside: +488.24%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $6.09
Upside: +228.41%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.42
Upside: +622.02%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $12.72
Upside: +175.16%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $11.21
Upside: +238.98%
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $23.83
Upside: +302.85%
Nektar Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $4
Current: $0.64
Upside: +525.00%
Cognition Therapeutics
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.37
Upside: +309.95%
Madrigal Pharmaceuticals
Nov 5, 2024
Maintains: Neutral
Price Target: $194 → $236
Current: $301.73
Upside: -21.78%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $6.00
Upside: +333.33%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $12.25
Upside: +169.39%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $4.54
Upside: +340.53%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $38.32
Upside: -11.27%
Jul 31, 2024
Downgrades: Neutral
Price Target: $18 → $5
Current: $1.27
Upside: +293.70%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $39.48
Upside: +133.03%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $4.02
Upside: -0.50%
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $6.02
Upside: -33.55%
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $0.19
Upside: +1,462.50%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $2.08
Upside: +7,592.31%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.79
Upside: +179.33%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $1.44
Upside: +2,955.56%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.51
Upside: +5,860.26%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $7.35
Upside: -4.76%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.27
Upside: +354,230.71%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $0.79
Upside: +33,939.33%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $10.51
Upside: +632.64%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.34
Upside: +107,362.69%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $1.38
Upside: +189.86%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $82.73
Upside: -52.86%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.45
Upside: +658.62%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.51
Upside: +868.66%